A pilot trial of oral topotecan (TPT) in patients with refractory advanced solid neoplasms expressing HIF-1α.

Authors:
  • ADA. G. Duffy
    A. G. Duffy
  • GMG. Melillo
    G. Melillo
  • BTB. Turkbey
    B. Turkbey
  • DAD. Allen
    D. Allen
  • PCP. L. Choyke
    P. L. Choyke
  • CCC. Chen
    C. Chen
  • MRM. Raffeld
    M. Raffeld
  • JDJ. H. Doroshow
    J. H. Doroshow
  • AMA. Murgo
    A. Murgo
  • SKS. Kummar
    S. Kummar

Abstract
E13518 Background: HIF-1α is a transcription factor that mediates tumor angiogenesis and survival. Previous studies have demonstrated that daily administration of topotecan (TPT) - a topoisomerase-1 inhibitor - inhibits HIF-1α expression, angiogenesis, and tumor growth in human xenograft models. The primary aim of this study is to investigate whether TPT inhibits HIF-1α expression in human cancers. Methods: TPT was administered orally at 1.6 mg/m2 daily × 5 for 2 weeks, of a 28-day cycle, to patients with advanced solid tumors expressing HIF-1α in at least 10% of tumor cells. Tumor biopsies were obtained before and after 2 cycles of TPT. The primary endpoint was modulation of HIF-1α expression by IHC. mRNA expression of HIF-1α target genes was assessed by real-time PCR. Radiologic correlative studies (comprising 18FDG-PET, to assess tumor metabolism, and DCE-MRI, to assess blood flow and permeability) were obtained at baseline, after 2 weeks of therapy and post cycle 2. The statistical significance of the...